We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

252 hedge funds and large institutions have $9.36B invested in Ultragenyx Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 97 increasing their positions, 72 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 16

267% more call options, than puts

Call options by funds: $59.6M | Put options by funds: $16.3M

80% more capital invested

Capital invested by funds: $5.2B → $9.36B (+$4.16B)

35% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 72

22% more funds holding

Funds holding: 206 → 252 (+46)

2.09% less ownership

Funds ownership: 104.36% → 102.28% (-2.1%)

Holders
252
Holders Change
+46
Holders Change %
+22.33%
% of All Funds
4.46%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
62
Increased
97
Reduced
72
Closed
16
Calls
$59.6M
Puts
$16.3M
Net Calls
+$43.4M
Net Calls Change
+$40.4M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$133M
2
BlackRock
BlackRock
New York
+$56.7M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$56.7M
4
BBA
Baker Bros. Advisors
New York
+$52.7M
5
Goldman Sachs
Goldman Sachs
New York
+$51.6M

Top Sellers

Rank Fund Capital Flow
1
Alkeon Capital Management
Alkeon Capital Management
New York
-$67.4M
2
Macquarie Group
Macquarie Group
Australia
-$23.2M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$23M
4
First Trust Advisors
First Trust Advisors
Illinois
-$20.6M
5
State Street
State Street
Massachusetts
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Neuberger Berman Group
101
Neuberger Berman Group
New York
$3.41M -$282K -2,373 -9%
Barclays
102
Barclays
United Kingdom
$3.26M -$8.79M -74,107 -76%
GGHC
103
Gilder Gagnon Howe & Co
New York
$3.22M +$2.76M +23,284 New
EI
104
EAM Investors
California
$2.64M +$220K +1,858 +11%
CM
105
Castleark Management
Illinois
$2.62M -$7.61M -64,190 -77%
SO
106
STRS Ohio
Ohio
$2.62M -$166K -1,400 -7%
Los Angeles Capital Management
107
Los Angeles Capital Management
California
$2.6M +$12K +101 +0.5%
Allianz Asset Management
108
Allianz Asset Management
Germany
$2.58M +$562K +4,740 +34%
GC
109
Guggenheim Capital
Illinois
$2.54M -$1.6M -13,486 -42%
EAM
110
Erste Asset Management
Austria
$2.54M -$142K -1,200 -7%
BNP Paribas Financial Markets
111
BNP Paribas Financial Markets
France
$2.5M -$1.97M -16,605 -48%
DekaBank Deutsche Girozentrale
112
DekaBank Deutsche Girozentrale
Germany
$2.48M -$183K -1,540 -8%
Tudor Investment Corp
113
Tudor Investment Corp
Connecticut
$2.45M +$205K +1,727 +11%
AP
114
AtonRa Partners
Switzerland
$2.44M +$2.09M +17,646 New
MLICM
115
Metropolitan Life Insurance Company (MetLife)
New York
$2.43M +$126K +1,059 +6%
AG
116
Aperio Group
California
$2.32M +$384K +3,238 +24%
ASRS
117
Arizona State Retirement System
Arizona
$2.31M -$51.6K -435 -3%
WM
118
WS Management
Florida
$2.31M – – –
Qube Research & Technologies (QRT)
119
Qube Research & Technologies (QRT)
United Kingdom
$2.29M +$1.97M +16,572 New
US Bancorp
120
US Bancorp
Minnesota
$2.07M +$1.27M +10,715 +254%
Walleye Trading
121
Walleye Trading
New York
$2.06M +$1.76M +14,849 New
SEI Investments
122
SEI Investments
Pennsylvania
$2.04M -$985K -8,303 -36%
VF
123
Virtu Financial
New York
$1.97M +$1.68M +14,202 New
Asset Management One
124
Asset Management One
Japan
$1.96M – – –
EF
125
Empowered Funds
Pennsylvania
$1.96M +$1.68M +14,165 New
3 4
5
6 7

RARE Hedge Fund Activity: Q4 2020 in Review

252 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2020, worth a combined $9.36B — up 80% from $5.2B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new RARE positions and 16 closed out — a net gain of 46 holders — while 97 added to existing stakes and 72 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $133M. The largest seller was Alkeon Capital Management, cutting an estimated $67.4M.

  • 252 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2020, up from 206 in Q3 2020.
  • Funds reported $9.36B of Ultragenyx Pharmaceutical stock for Q4 2020, up 80% quarter-over-quarter.
  • 62 funds opened new Ultragenyx Pharmaceutical positions in Q4 2020 and 16 closed out, a net change of +46 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2020 was T. Rowe Price Associates, an estimated $133M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2020 was Alkeon Capital Management, an estimated $67.4M sold.

Based on aggregated 13F filings for Q4 2020.